“We are very pleased to be working with Foresight.
Whilst our software meets many of these needs already, this investment means we can significantly accelerate our development and deployment programmes.”
NWEH’s innovative technology seeks to reduce the cost of running clinical trials and increase the efficiency of clinical trials, in turn contributing to improved medical treatment and a healthier population.Ĭommenting on the investment, Martin Gibson, CEO of NWEH, said: “The pandemic has strengthened the need for increased data integration to enable rapid trial design, recruitment and remote follow-up.
The UK is one of the leading global markets for clinical trials, currently worth £3 billion per year, with life sciences identified as a priority sector by the UK Government post-Brexit.įoresight is committed to working towards a smarter future by supporting SMEs with the potential to have a positive impact on society. The market opportunity is vast, with global clinical trials estimated to be worth $69 billion annually and forecast to grow at a rate of 5.7% per year until 2026. The existing team have strong credentials in their field and are led by founder and CEO Martin Gibson.Ĭustomers include several of the largest global pharmaceutical and research companies, such as GSK, Novartis and PPD. The investment will be used to expand the current data network, enabling the Company to deliver a larger number of trials at a global level, increase product development and expand the sales and marketing team to help build long term, strategic relationships. With Foresight’s support, NWEH aims to become a leading provider of clinical trials and data-driven trial design, feasibility and recruitment. NWEH’s leading-edge technologies help run trials more cost effectively, from feasibility studies to the World’s first large scale Phase III trial using data directly from source electronic health records (EHR).
Its products provide the life sciences industry with an alternative approach to clinical trial design and management. London 23 June 2021: Foresight Group, an award-winning listed infrastructure and private equity investment manager, has invested £3.0 million of growth capital into NorthWest EHealth Limited (“NWEH” or “the Company”), providers of software and services to the clinical trials market.Įstablished in 2016, NWEH grew out of a collaboration between the University of Manchester, Salford Royal Foundation NHS Trust and Salford Clinical Commissioning Group. Investment will be used to help expand data networks, sales and marketing and further product development NorthWest EHealth provides the life sciences industry with an alternative approach to the design and management of clinical trials, safely accelerating drug development programmesĪ pioneering business that can deliver remote trials in a post-COVID world